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Radiogenomics Profiling for 
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and Prognosis
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Although there have been a plethora of radiogenomics studies related to glioblastoma (GBM), most of 
them only used genomic information from tumor cells. In this study, we used radiogenomics profiling 
to identify MRI-associated immune cell markers in GBM, which was also correlated with prognosis. 
Expression levels of immune cell markers were correlated with quantitative MRI parameters in a total 
of 60 GBM patients. Fourteen immune cell markers (i.e., CD11b, CD68, CSF1R, CD163, CD33, CD123, 
CD83, CD63, CD49d and CD117 for myeloid cells, and CD4, CD3e, CD25 and CD8 for lymphoid cells) 
were selected for RNA-level analysis using quantitative RT-PCR. For MRI analysis, quantitative MRI 
parameters from FLAIR, contrast-enhanced (CE) T1WI, dynamic susceptibility contrast perfusion MRI 
and diffusion-weighted images were used. In addition, PFS associated with interesting mRNA data 
was performed by Kaplan-Meier survival analysis. CD163, which marks tumor associated microglia/
macrophages (TAMs), showed the highest expression level in GBM patients. CD68 (TAMs), CSF1R 
(TAMs), CD33 (myeloid-derived suppressor cell) and CD4 (helper T cell, regulatory T cell) levels were 
highly positively correlated with nCBV values, while CD3e (helper T cell, cytotoxic T cell) and CD49d 
showed a significantly negative correlation with apparent diffusion coefficient (ADC) values. Moreover, 
regardless of any other molecular characteristics, CD49d was revealed as one independent factor for 
PFS of GBM patients by Cox proportional-hazards regression analysis (P = 0.0002). CD49d expression 
level CD49d correlated with ADC can be considered as a candidate biomarker to predict progression of 
GBM patients.
The most aggressive form of brain cancer, called glioblastoma (GBM), is highly invasive and spreads rapidly, 
which makes it difficult to remove completely. GBM is also characterized by heterogeneity, angiogenesis, and 
strengthened cell proliferation. Although there have been many efforts of research and multi-modality treatment 
with surgical resection followed by chemotherapy and radiation therapy, patients average approximately 1 year of 
survival time1. Accordingly, targeting the tumor microenvironment (TME) of GBM is an emerging approach to 
overcome tumor resistance against the standard treatment2–5.
In the context of immune cells in TME, there are two major lineages of cells. One is the myeloid lineage, 
including macrophages, neutrophils, myeloid-derived suppressor cells (MDSC), dendritic cells (DC) and mast 
cells, and the other is the lymphoid lineage, including CD4+ helper T cells, regulatory T cells and CD8+ cyto-
toxic T cells, which have distinct functions during tumorigenesis6–8. Inter alia, macrophages and T cells present 
the most noticeable characteristics among the immune cells in TME. As noted in several studies9–13, there are 
two types of macrophages, M1 type and M2 type. The function of each type of macrophage around the tumor 
is significantly different. Pro-inflammation is the major characteristic of the M1 type, which is correlated with 
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anti-tumorigenic functions in TME. In contrast, the main feature of the M2 type is anti-inflammation, which 
correlates with the pro-tumorigenic function in TME. Thus, they are known as tumor associated microglia/
macrophages (TAMs), whose presence in tumors supports angiogenesis and invasion9–13. Helper T cells are 
also classified into two different types. Type 1 helper T cells (TH1) secrete pro-inflammatory cytokines and 
can be anti-tumorigenic; on the other hand, type 2 helper T cells (TH2) could be pro-tumorigenic by secreting 
anti-inflammatory cytokines, indicating that the ratio of TH1 to TH2 is crucial for tumor stage and grade8,9,13,14. As 
such, determining the various roles of TME immune cells has come to the light as a key point for diagnosis and 
prediction of cancer progression8.
CD system which was established in the 1st International Workshop and Conference on Hyman leukocyte 
Differentiation Antigen (HLDA) is commonly used as cell markers in immunophenotyping15,16. It allows cells to 
be defined based on what molecules are present on their surface and to be often used to associate cells with certain 
immune functions regardless of HLA diversity of each patients17. Here, we chose fourteen CD markers based on 
the previous paper for identifying immune cells8.
Radiogenomics is the study linking medical images with the genomic profiles of human tumors. It has several 
benefits in terms of providing opportunities for non-invasive diagnostics and prognostics. For example, through 
radiogenomics, we could uncover imaging biomarkers that can identify the genomics of a disease, especially 
cancer, without using a biopsy18. Recently, although there have been a plethora of radiogenomics studies related 
to GBM, most of them used genomic information of tumor cells, not immune cells19–22. As 30-50% of the cells 
in gliomas are immune cells23–27, disclosing the information of immune cells in TME is important to understand 
fundamental details of the tumor-host interaction and predict the prognosis. Furthermore, provided that we are 
able to obtain immune cell information via the MRI findings, which is the general diagnostic method for brain 
tumors, it should contribute to both GBM diagnosis and treatment.
In this study, we used radiogenomics profiling to identify MRI-associated immune cell markers in GBM, 
which was also correlated with prognosis.
Results
Clinical characteristics of the GBM patients. The baseline epidemiologic and molecular characteristics 
are shown in Table 1. In brief, 35 male and 25 female patients with mean age of 54.22 ± 11.39 years at diagnosis of 
GBM were enrolled for this study. GBMs were predominantly located at the supratentorial brain (97%, n = 59), 
including frontal lobe (55%, n = 33), parietal lobe (35%, n = 21), temporal lobe (57%, n = 34), occipital lobe (7%, 
n = 4), insula (13%, n = 8), deep gray matter (23%, n = 14), corpus callosum (13%, n = 8) and mid-brain (8%, 
n = 5). In molecular characteristics, nine (15%) and two (3%) patients (15%) presented IDH1- and IDH2-mutated 
tumors, respectively. Half of the patients (n = 30) had MGMT promoter methylation, and 13 patients showed 
ATRX mutation, while none of patients had 1p/19q co-deleted tumor.
Immune cell RNA expression level in GBM. Normalized expression levels of CD11b, CD68, CSF1R, 
CD163, CD33, CD123, CD83, CD63, CD49d, CD117, CD4, CD3e, CD25 and CD8 in each patient were summa-
rized in Fig. 1. We found that myeloid lineage immune cell markers were more dominant than lymphoid line-
age markers. Among the myeloid lineage immune cell markers, CD163, CD63, CD83 and CD49d showed RNA 
expression levels of more than 10%.
TAM and T cell markers correlated with nCBV, ADC, volume and necrosis values. We performed 
Pearson’s correlation analysis to determine the association between immune cell markers and MRI parameters, 
and Fig. 2A, Supplementary Fig. 1 and Table 2 summarize the correlation. The expression levels of CD68, CSF1R, 
CD33 and CD4 showed significant positive correlations with nCBV values based on both region of interests 
(ROIs) from FLAIR and CE T1WI and that of CD11b had a significant positive correlation with nCBV values 
only from CE T1WI (Fig. 2B; Case 1 and 2). We found significant negative correlations between the expression 
levels of CD49d and CD3e and ADC values from both FLAIR and CE T1WI, and those of CD33 and CD123, and 
CD25 were negatively correlated with ADC values from FLAIR and CE T1WI, respectively (Fig. 2B; Case 3 and 
4). Tumor volumes based on FLAIR or CE T1WI had significant negative correlations with the expression levels 
of CD123, CD49d and CD117, but no immune cell markers showed a significant correlation with tumor necrosis 
or necrosis ratio.
Immune cell makers correlated with PFS. PFS was correlated with fourteen immune cell markers, and 
eight makers showed statistical significance (P < 0.05), including myeloid cell markers (e.g., CD11b, CD123, 
CD33, CD163, CD63 and CD49d) and lymphoid cell marker genes (e.g., CD25 and CD8). Each gene expres-
sion level of higher threshold was associated with poor PFS (Fig. 3, Supplementary Fig. 2, and Supplementary 
Tables 1-3). Then, we executed Cox proportional hazards model analysis, including eight genes significantly asso-
ciated with PFS and previously reported prognostic factors (e.g., IDH1, IDH2, 1p/19q, MGMT and ATRX status) 
(Table 3), which revealed that only CD49d was significant among thirteen covariates (Table 2, P = 0.0007). In all 
patients, there was a significant difference in PFS between low and high CD49d expression tumors (median, 25.1 
[95% CI, 12.3-25.1] vs 7.5 [95% CI, 3.5-10.6] months; P = 0.0002, log-rank test), which was independent of IDH1 
mutation status (Fig. 3 and Supplementary Tables 2 and 3).
Discussion
In this study, we applied radiogenomics profiling to the association between quantitative MRI features and 
expression levels of immune cell markers in GBM patients, which was also correlated with PFS. We found that 
myeloid lineage immune cell markers (e.g., CD163, CD63, CD83 and CD49d) were more dominant than lym-
phoid lineage markers in GBMs. In terms of CBV values based on FLAIR or CE T1WI, the expression levels of 
CD68, CSF1R, CD33, CD4 and CD11b showed positive correlations. In addition, the expression levels of CD49d, 
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CD3e, CD33, CD123 and CD25 were found to have negative correlations with ADC values based on FLAIR or 
CE T1WI. The expression levels of CD123, CD49d and CD117 had negative correlations with tumor volumes. 
PFS was also correlated with myeloid cell markers (e.g., CD11b, CD123, CD33, CD163, CD63 and CD49d) and 
lymphoid cell marker genes (e.g., CD25 and CD8). Among them, CD49d was the most important prognostic 
marker regardless of genetic status of GBM.
TAMs are known to have a role in tumor angiogenesis; therefore, we assumed that TAMs can affect the 
increase in nCBV values, which can be simultaneously correlated with TAM markers (e.g., CD11b, CD68 and 
CSF1R). Recent studies have elaborated an important role of CSF1R-colony stimulating factor-1 receptor in the 
brain TAM; for example, inhibition of CSF1R either reduces28 or depolarizes TAMs29. In addition, CD33, a MDSC 
marker, has high correlation with nCBV values. The suppressive activity of MDSC is one of the most prevalent 
mechanisms of immune evasion in patients30, which occurs as a consequence of the aberrant myelopoiesis that 
arises in cancer. MDSCs are mobilized during tumorigenesis and infiltrate developing tumors, where they pro-
mote tumor angiogenesis31 and disrupt major immunosurveillance mechanisms. Among the lymphoid lineage 
markers, CD4 is significantly positively correlated with nCBV values. As we described above, nCBV seem to 
be related to the function of TAMs, which induce angiogenesis in tumors. Regulatory T cell and type 2 helper 
T cells (TH2) marked by CD4 express Interleukin-1032, Interleukin-4 and Interleukin-1333, which are cytokines 
for M2-type macrophage polarization11,34,35. In other words, TAMs can be induced primarily by pro-tumorigenic 
roles through suppressive immunosurveillance and anti-inflammatory cytokines, which can cause increase in 
nCBV resulting from angiogenesis, one of the key roles of TAMs in GBM10,23.
CD49d, CD33, CD123, CD3e, and CD25, which mark bone marrow-derived cells (MDSCs) dendritic cells 
(DC), T helper cells, cytotoxic T cells and regulatory T cells, respectively, are negatively correlated with ADC 
values. Dendritic cells are known as antigen presenting cells derived from the bone marrow, which induces innate 
and adaptive immune responses36. When tumors occur, immune cells, including MDSCs, which are the precur-
sor of DCs, macrophages and granulocytes9,12,13, DCs and T cells, are recruited from bone marrow and converge 
Characteristics N
Age 54.22 ± 11.39*
Sex
    Male 35
    Female 25
Tumor location**
    Supratentorial 59
            Frontal 33 (24)
            Parietal 21 (18)
            Temporal 34 (22)
            Occipital 4 (4)
            Insula 8 (7)
            Deep gray matter 14 (14)
            Corpus callosum 8 (8)
            Mid-brain 5
    Infratentorial 2
            Infratentorial 2 (1)
Histopathologic assay
    IDH1
            mutant 9
            wildtype 51
    IDH2
            mutant 2
            wildtype 58
    1p/19q
            co-deleted 0
            non co-deleted 60
    MGMT promoter
            methylated 30
            unmethylated 30
    ATRX
            mutant 13
            wildtype 47
Table 1. Characteristics of 60 patients with glioblastoma multiforme. *Mean value ± standard deviation. **The 
tumor locations were classified according to the tumor epicenter. Parentheses: the number of patients with 
tumors involving more than one location.
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on the tumor side by the immune system13. We believe that tumor cellularity, measured by ADC value, can be 
affected by immune cell infiltration as well as tumor tissue itself. In addition, myeloid cells seem to play a more 
important role than lymphoid cells in tumor cellularity.
In addition, CD123, CD117, and CD49d, which mark DCs, mast cells and bone marrow-derived cells8, respec-
tively, are negatively correlated with tumor volume. Before they are recruited by tumors, DCs and mast cells 
induce innate and adaptive immune responses to regress tumors and prevent relapse9. CD49d was revealed as a 
marker of hematopoietic bone marrow-derived cells37. DCs and mast cells activate T cells to remove tumors8,12, 
which can be explained by the finding that these immune cells recruit in the early stage of gliomagenesis.
In terms of PFS, as the previous study has been reported that high CD49d expression is associated with poor 
survival in chronic lymphocytic leukemia38, it is remarkable that CD49d was discovered an independent bio-
marker regardless of any other molecular characteristics, even though TAM markers are prominent among the 
immune cell population and correlate with several imaging features. CD49d is also known as integrin α4, form-
ing a heterodimer with integrin β1 (VLA4), which is the specific marker of hematopoietic cells, namely, bone 
marrow-derived cells. Bowman RL et al. demonstrated that microglia specifically repress integrin α4 (CD49d), 
enabling its utility as a discriminatory marker between microglia and bone marrow-derived macrophages in 
primary and metastatic disease in both mouse and human37. Several studies reported that the brain-resident 
microglia and the infiltrating monocytes/macrophages of blood are the major glioma-associated inflammatory 
cells that constitute the tumor microenvironment39,40. Particularly, a recent report41 and a clinical study42 revealed 
that monocytes/macrophages, but not microglia and lymphocytes, are the most predominant TAMs in GBM. 
Monocytes, cells of the myeloid lineage, are released during inflammation and differentiate into macrophages to 
maintain immune homeostasis43. A previous study suggested that circulating monocytes are cytotoxic to tumor 
cells44; however, when monocytes reach the tumor mass, the tumor molecular milieu induces differentiation to 
new cell types per tumor requirement45. A recent report indicated that reduction in the tumor-promoting effects 
of monocytes/macrophages in GBM can be considered as an adjuvant treatment for glioma46. However, the fate 
of the GBM-adhered monocytes/macrophages and their effect on GBM growth are still obscure. Adhesion mole-
cules are known to mediate cell–cell interactions, particularly between immune cells and target tissues. Vascular 
cell adhesion molecule-1 (VCAM-1) is an inducible adhesion molecule that facilitates tight attachment to the 
monocyte/macrophage-associated integrin α4β1 (VLA4)47. VCAM-1 expressed on the surface of tumors inter-
acts with VLA4 on monocytes/macrophages, which promotes tumor invasion, angiogenesis and metastasis10. In 
short, higher CD49d expression level in GBM is thought to induce TAMs to adhere to GBM, increasing cellularity 
and resulting in a decrease in ADC on MRI, attenuated tumor aggressiveness and poorer progression of patients. 
The previous studies have been reported that MRI parameters (e.g., nCBV and ADC) are used for evaluation of 
GBM patients’ overall survival (OS) and PFS and they are related to poor progression of GBM. For instance, high 
nCBV and low ADC values are results of poor PFS48. Therefore, our findings related to immune cell markers and 
MR imaging parameters can follow antecedent researches.
There are some limitations in this study in addition to the retrospective design. First, in this study, we did 
not perform experiments providing direct evidence to show the relationship between immune cell migration, 
angiogenesis and cellularity. Thus, future study is warranted. Second, we could not see the interactions between 
immune and cancer cells, which need further in vitro and in vivo experiments to be translated to future clinical 
studies.
Figure 1. Illustration of age, gender, tumor location, genetic information and normalized RNA expression level 
of immune cell markers in each patient.
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Our radiogenomics profiling reveals that immune cell markers such as TAM markers have significant cor-
relations with nCBV and ADC values, and CD49d expression level correlated with ADC can be considered as a 
candidate biomarker to predict progression of GBM patients. We believe that our results can be used for under-
standing the GBM microenviroment and development of evaluation and treatment strategies.
Figure 2. Illustration of correlation between MRI parameters and immune cell markers (A), and representative 
cases (B). (A) Case 1 and Case 2 show high and low expression level of CD68, CSF1R, CD33 and CD4, 
respectively, which have significant correlation with nCBV values. In Case 3 and Case 4, high and low 
expression levels of CD33, CD123, CD49d and CD3e are significantly correlated with ADC values.
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Methods
This retrospective human study was approved by the institutional review board of Seoul National University 
Hospital, which waived the requirement of obtaining informed consent.
Patient population. Between August 2012 and December 2015, 258 patients who were initially diagnosed 
with GBM at our institution were consecutively recruited. The inclusion criteria were as follows: the patient (a) 
had a histopathologic diagnosis of GBM without other cell components based on the World Health Organization 
2016 criteria; (b) underwent conventional, diffusion-weighted imaging (DWI) and DSC perfusion MR imaging 
24-48 hours before surgery; (c) had available tumor samples in the brain tumor bank of our institute; and (d) 
underwent the standard treatment of near-total resection, concomitant chemoradiotherapy (CCRT) and adjuvant 
temozolomide medication. As a result of these inclusion criteria, 60 patients were included in our study. All tumor 
samples used in this study were snap-frozen in liquid nitrogen as soon as possible during the surgery and stored 
at −80 °C.
RNA isolation and real-time PCR. The total RNA of each tissue sample was isolated using the QIAquick 
RNeasy Mini kit (Qiagen) according to the manufacturer’s instructions, and the quality of the RNA was verified 
by an Agilent 2100 Bioanalyzer (Agilent Technologies). Reverse transcription was performed with RevertAid H 
Minus Reverse Transcriptase (Thermo). Briefly, reverse transcription was carried out in a volume of 100 μl with 
2.0 μg RNA, 15 pmol of oligo deoxythymidine primer, 20 µl of 5Χ RT Buffer, and 20 μl each of 2.5 mM dNTP mix, 
RNase inhibitor, and reverse transcriptase. RT conditions were as follows: 10 minutes at 65 °C, 60 minutes at 42 °C, 
10 minutes at 25 °C, and 10 minutes at 70 °C.
Real-time PCR was performed in a Rotor-Genes Q cycler machine (Qiagen) using Rotor-Genes SYBR Green 
PCR kit (Qiagen) according to the manufacturer’s instructions in a total volume of 20 µl. Cycling conditions for 
the immune cell markers and GAPDH were 10 minutes at 95 °C, 40 cycles of 10 seconds at 95 °C, 15 seconds at 
optimal Tm, and 20 seconds at 72 °C. The sequences of the primers were as follows:
CD11b; 5′-caactatggagaatggtcctaagct-3′/5′-tgtccagtcgctctcttctcttc-3′, CSF1R; 5′-tttggggctagacagactgg-3′/5′-cctg 
agctgagtgtggtctg-3′, CD123; 5′-gggggtctgcctcaatct-3′/5′-caccacccgttaggaatgtc-3′, CD33; 5′-tttaacaccccacaggcaat-3′/ 
5′-gcacagatttgattccacga-3′, CD3e; 5′-tccctaccaaccccctaatc-3′/5′-tacggagatgcaaatgacca-3′, CD25; 5′-agtttt 
cagcagggtccaga-3′/5′-ggggagagtgcacagatgag-3′, CD8; 5′-ctggcctctgctcaactagc-3′/5′-gaagtgcatgtttgggacag -3′, 
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CD11b
r 0.179 0.203 −0.176 0 0.255 0.271 −0.243 −0.088 −0.074 −0.199 −0.122 −0.13 −0.08
P 0.1702 0.1205 0.1787 0.9994 0.0494 0.0363 0.0616 0.5054 0.5747 0.127 0.3534 0.3207 0.5439
CD68
r 0.254 0.292 −0.084 0.035 0.232 0.301 −0.028 0.033 0.248 0.087 0.115 −0.05 0.044
P 0.0505 0.0236 0.5249 0.7926 0.0746 0.0196 0.8311 0.8026 0.0556 0.5097 0.38 0.7062 0.7407
CSF1R
r 0.364 0.385 −0.101 0.075 0.366 0.404 −0.017 0.125 −0.036 −0.148 −0.061 −0.138 −0.046
P 0.0043 0.0024 0.4408 0.5678 0.0041 0.0014 0.8956 0.3406 0.7829 0.2604 0.6444 0.2917 0.7246
CD163
r −0.084 −0.002 0.118 0.154 0.119 0.069 0.048 0.214 0.245 0.068 −0.027 −0.163 −0.156
P 0.5231 0.9879 0.3704 0.2411 0.3653 0.5984 0.7177 0.1002 0.0589 0.6039 0.8361 0.213 0.2326
CD33
r 0.354 0.305 −0.321 −0.11 0.303 0.302 −0.233 −0.046 −0.197 −0.141 −0.015 0.041 0.049
P 0.0056 0.0178 0.0125 0.403 0.0186 0.0189 0.0726 0.7284 0.1322 0.2839 0.9112 0.7549 0.7112
CD123
r 0.125 0.025 −0.279 −0.117 0.047 0.015 −0.213 −0.057 −0.169 −0.273 −0.161 −0.095 −0.027
P 0.3416 0.8514 0.0306 0.3713 0.7189 0.9084 0.1022 0.6642 0.1981 0.0345 0.2205 0.468 0.8393
CD83
r 0.175 0.047 −0.241 −0.133 0.045 0.034 −0.028 0.066 −0.122 −0.229 −0.11 0.014 −0.005
P 0.1814 0.7223 0.064 0.3098 0.7323 0.7952 0.8293 0.6157 0.354 0.0781 0.4025 0.9154 0.9689
CD63
r 0.054 0.037 −0.24 −0.089 0.073 0.036 −0.187 −0.062 −0.182 −0.229 −0.03 0.014 0.064
P 0.6794 0.7787 0.0646 0.5012 0.5813 0.7837 0.1536 0.6384 0.1642 0.0782 0.8218 0.914 0.6273
CD49d
r 0.034 −0.003 −0.278 −0.233 0.081 0.038 −0.284 −0.169 −0.217 −0.291 −0.223 −0.234 −0.106
P 0.7971 0.9821 0.0314 0.0736 0.5373 0.7713 0.0281 0.1974 0.0961 0.0242 0.087 0.0718 0.4184
CD117
r −0.007 −0.044 −0.212 −0.053 −0.015 0.014 −0.001 0.012 −0.278 −0.271 −0.133 −0.079 −0.092
P 0.9554 0.7397 0.104 0.6859 0.9118 0.9138 0.9961 0.9245 0.0313 0.036 0.311 0.5461 0.4859
CD4
r 0.447 0.431 −0.149 −0.09 0.433 0.433 −0.163 −0.166 −0.069 −0.118 −0.055 −0.048 0.018
P 0.0003 0.0006 0.2551 0.4934 0.0005 0.0005 0.2137 0.2049 0.5986 0.37 0.6789 0.7167 0.8896
CD3e
r −0.005 −0.015 −0.301 −0.3 0.024 0.026 −0.376 −0.304 −0.099 −0.082 −0.016 −0.034 −0.041
P 0.9686 0.9085 0.0195 0.0197 0.8552 0.8419 0.0031 0.0181 0.4511 0.5324 0.9023 0.7968 0.7567
CD25
r 0.118 0.145 −0.204 −0.168 0.209 0.166 −0.33 −0.215 −0.031 −0.055 −0.146 −0.087 −0.139
P 0.3677 0.2697 0.1179 0.1991 0.1098 0.2051 0.01 0.0985 0.8113 0.6787 0.2644 0.5101 0.2896
CD8
r 0.107 0.095 −0.191 −0.133 0.13 0.128 −0.094 0.058 −0.061 −0.233 −0.213 −0.21 −0.207
P 0.4167 0.4696 0.1445 0.3105 0.3206 0.3311 0.4751 0.6605 0.6418 0.0727 0.1027 0.1075 0.1134
Table 2. Correlation analysis between immune cell markers and MRI values. r: Pearson correlation coefficient.
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Figure 3. Kaplan-Meier estimates of PFS according to the CD49d expression level (A and B) and representative 
cases (C). PFS of GBM patients with low expression level of CD49d (≤170) was significantly longer than that 
of patients with high expression level of CD49d (>170) (A), which was independent of IDH1 mutation status 
(B). In all patients, there was a significant difference in PFS between low and high CD49d expression tumors 
(median, 25.1 [95% CI, 12.3-25.1] vs 7.5 [95% CI, 3.5-10.6] months; P = 0.0002, log-rank test). Patients with 
IDH1-wildtype GBMs also had a significant difference in PFS between low and high CD49d expression tumors 
(median, 18.7 [95% CI, 11.0-18.7] vs 7.5 [95% CI, 3.5-12.3] months; P = 0.0025, log-rank test). In patients with 
IDH1-mutant GBMs, there was also a significant difference in PFS between low and high CD49d expression 
tumors (median, 25.1 [95% CI, 11.7-25.1] vs 3 months; P = 0.0047, log-rank test). (C) Case 1 and Case 2 show 
high and low expression level of CD49d, respectively, which is negatively correlated with ADC mean values 
based on both FLARI and CE T1WI and tumor volume on CE T1WI. (D) Immunohistochemistry results for 
CD49d are correlated with CD49d RNA expression level. (Glial fibrillary acidic protein: GFP, CD49d: RFP, 
nucleus: DAPI).
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CD68; 5′-aaagtttctcctgccccagt -3′/5′-gcagaaagcaataagcacca-3′, CD163; 5′-tgagccacactgaaaaggaa-3′/5′-gctccattcaata 
gtccaggtc-3′, CD83; 5′-caggtccacggtctgttctt-3′/5′-cttcgtgaagtcccttctgc-3′, CD63; 5′-tttgtcgaggttttgggaat-3′/5′-cagat 
gaggaggctgaggag-3′, CD49d; 5′-taccaagaatgcgtttgcag-3′/5′-gagcattcaacttcccttgg-3′, CD117; 5′-ccagaagcttcc 
atagtggtg-3′/5′-agtgccttaagtgcaggtgaa-3′, CD4; 5′-ggctctcaccagtggctagt-3′/5′-ccttcatccctgctcgtaaa-3′ and GAPDH; 
5′-ggcattgctctcaatgacaa-3′/5′-atgtaggccatgaggtccac-3′. A standard curve was generated and a nontemplate control 
was run with every assay to correlate the threshold (Ct) values from the amplification plots to copy number. All 
samples were run in duplicate, and the average value was used.
We normalized immune cell markers by the highest expressed marker in each patient.
MRI protocol. All patients underwent conventional, DWI and DSC perfusion MRI using a 3 T scanner 
(Verio; Siemens Healthcare Sector) with a 32-channel head coil. The conventional MRI included T1-weighted 
imaging (T1WI), such as transverse spin-echo imaging, before and after contrast enhancement or multi-planar 
reconstructed transverse, coronal imaging with a sagittal three-dimensional magnetization prepared rapid 
acquisition gradient echo (3D-MPRAGE) sequence before and after contrast enhancement, and transverse 
T2-weighted imaging (T2WI) with turbo spin-echo sequences and FLAIR images. Contrast-enhanced (CE) 
T1WI was acquired after the intravenous administration of gadobutrol (Gadovist®, Bayer Schering Pharma) 
at a concentration of 0.1 mmol per kilogram (mmol/kg) of body weight. The transverse spin-echo T1-weighted 
imaging was obtained with the following parameters: repetition time (TR), 558 ms; echo time (TE), 9.8 ms; flip 
angle (FA), 70°; matrix, 384 × 187; field-of-view (FOV), 175 × 220 mm; section thickness, 5 mm; and number of 
excitations (NEX), 1. We obtained the 3D-MPRAGE sequences using the following parameters: TR, 1500 ms; TE, 
1.9 ms; FA, 9°; matrix, 256 × 232; FOV, 220 × 250; section thickness, 1 mm; and NEX, 1. The parameters of the 
transverse T2-weighted imaging were as follows: TR, 5160 ms; TE, 91 ms; FA, 124-130°; matrix, 640 × 510–580; 
FOV, 175-199 × 220; section thickness, 5 mm; and NEX, 3. The parameters for transverse FLAIR were a TR of 
9000 ms, a TE of 97 ms, a TI of 2500 ms, an FA of 130°, a matrix of 384 × 348, an FOV of 199 × 220, a section 
thickness of 5 mm and an NEX of 1.
DWI was performed with a single-shot, spin-echo, echo-planar imaging (EPI) sequence in the axial plane 
before the injection of contrast material with b-values of 0 and 1000 sec/mm2, a TR of 6300 ms, a TE of 92 ms, 
an FA of 180°, a matrix of 240 × 240, an FOV of 240 × 240, a section thickness of 3 mm and an NEX of 3. DWI 
was acquired in three orthogonal directions and combined into a trace image. ADC maps were calculated on a 
voxel-by-voxel basis with the software that was incorporated into the MRI unit using these data.
The transverse DSC perfusion MRI was obtained with single-shot, gradient-echo, echo-planar sequences 
during the intravenous administration of gadobutrol at a concentration of 0.1 mmol/kg of body weight at a rate 
of 4 ml/sec using a power injector (Spectris; Medrad). A 30-ml bolus injection of saline followed at the same 
injection rate. For each section, 60 images were acquired at intervals equal to the TR. The parameters were as fol-
lows: TR, 1500 ms; TE, 30 ms; FA, 90°; matrix, 128 × 128; section thickness, 5 mm; intersection gap, 1 mm; FOV, 
240 × 240 mm; sections, 15-20; voxel size, 1.875 × 1.875 × 5 mm3; pixel bandwidth, 1563 Hz; and total acquisition 
time, 1 minute 30 seconds.
Image post-processing and data analysis. The conventional MR images, ADC maps, and DSC PWI 
were digitally transferred from the picture archiving and communication system workstation to a personal com-
puter for further analysis. The relative CBV (rCBV) was obtained with a dedicated software package (nordicICE; 
Nordic Imaging Lab, Bergen, Norway) that applied an established tracer kinetic model to the first-pass data49,50. 
First, realignment was performed to minimize patient motion during the dynamic scans. A gamma-variate func-
tion, which approximates the first-pass response as it would appear in the absence of recirculation, was used to fit 
the 1/T2* curves to reduce the effects of recirculation. To reduce the contrast agent leakage effects, the dynamic 
curves were mathematically corrected by using leakage correction package available on the dedicated software51. 
After the elimination of recirculation and leakage of the contrast agent, rCBV was computed with numeric inte-
gration of the curve. To minimize variances in rCBV in an individual patient, the pixel-based rCBV maps were 
normalized by dividing every rCBV value in a specific section by the rCBV value in the unaffected white matter, 
and finally normalized rCBV (nCBV) maps were generated52.
Using a dedicated software package (nordicICE), co-registrations between the structural images (e.g., FLAIR 
images and CE T1WI) and the nCBV and ADC maps were performed based on geometric information stored 
in the respective data sets. The differences in the slice thickness between images were corrected automatically by 
re-slicing and co-registration based on the underlying structural images. The nCBV and ADC maps were dis-
played as color overlays on the both FLAIR images and CE T1WI.
One neuroradiologist (S.H.C. with 16 years of brain MR imaging experience) who was blinded to the clinical 
data drew polygonal ROIs that contained the entire enhancing lesions in each section of the co-registered images. 
Areas of necrosis, hemorrhage, or non-tumor macro-vessels that were evident on the CE T1WI were excluded 
from the ROIs. Then, the ROIs of T2 high SI lesions, regardless of contrast enhancement, were also defined on 
each transverse FLAIR image, avoiding the cystic and necrotic regions and the macrovessels. Because the ROI 
placement was conducted on the nCBV and ADC map co-registered with structural images, the margin of the 
Covariate b SE P Exp (b) 95% CI of Exp (b)
CD49d expression level (≥170) 1.3476 0.3954 0.0007 3.848 1.7728 to 8.3525
Table 3. Results of Cox proportional hazards model analysis. b - coefficient estimates; 95% CI - 95% confidence 
interval. Exp(b) - hazard ratio value; SE - standard error of coefficient estimates b.
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lesions could be defined with confidence. The entire volume of contrast-enhancing lesions, T2 high SI lesions, and 
necrosis, which was defined as a hypointense area without contrast enhancement on CE T1WI within the mass 
on the FLAIR images, was calculated.
The data acquired from each section were summed to derive the voxel-by-voxel ADCs and nCBVs for the 
entire tumor extent based on both CE T1WI and FLAIR images by using nordic ICE. The ADC and nCBV his-
tograms were plotted with ADC and nCBV on the respective x-axis with a bin size of 3 × 10−5 mm2/sec and 0.1, 
respectively, whereas the y-axis was expressed as a percentage of the total lesion volume by dividing the frequency 
in each bin by the total number of analyzed voxels. For further quantitative analysis, the cumulative number 
of observations in all bins up to the specified bin was mapped on the y-axis as a percentage in the cumulative 
histograms. The 5th percentile point for ADC (5% ADC) and 95th percentile point for nCBV (95% nCBV) were 
derived (the Xth percentile point is the point at which X% of the voxel values that form the histogram are found 
to the left of the histogram)53,54.
Immunohistochemistry staining. Antibodies for IHC analysis included mouse anti-human Integrin 
alpha4 (CD49d) antibody (sc-365209, Santa Cruz Biotechnology, Inc.) and rabbit anti-human Glial fibrillary 
acidic protein (GFAP) antibody (ab7260, abcam). Paraffin sections (4 μm) were dewaxed and rehydrated, Antigen 
retrieval was performed in a microwave by placing the sections in epitope retrieval solution (0.01 M citrate buffer, 
pH 6.0) for 20 minutes, then incubated in 3% hydrogen peroxide for 20 min at room temperature. The paraffin 
sections were then blocked with 3% BSA for 30 min, stained with antibodies for 1 hour at room temperature, 
washed with wash buffer (S3006, Dako) and stained with secondary antibody (A-11008, Alexa Fluor 488 by 
InvitrogenTM; A-11032, Alexa Fluor 594 by InvitrogenTM) for 30 min at room temperature. DAPI was used to stain 
the nucleus.
Statistical Analysis. All statistical analyses were performed using two commercial software pro-
grams (MedCalc version 17.2, MedCalc Software). A P value < 0.05 was considered statistically signifi-
cant. Kolmogorov-Smirnov’s test was used to determine whether the variables followed normal distribution. 
Non-parametric data are presented as median and interquartile range (IQR, range from the 25th to the 75th 
percentile), and parametric data are shown as the mean ± standard deviation. Pearson’s correlation analysis for 
parametric data was performed for the correlation between the expression level of immune cell markers and 
quantitative imaging parameters.
The progression-free survival (PFS) was assessed using the Kaplan-Meier method according to the expression 
level of immune cell markers, which were compared using log-rank tests. GBM progression was defined accord-
ing to RANO criteria55. We only recorded the first progression. PFS was calculated from the date of surgery to 
that of GBM progression, death, the last confirmation of no evidence of disease, or the most recent follow-up 
examination. Patients without an event were censored at the date of the most recent follow-up, regardless of 
whether they were scheduled for future follow-up or they had been lost to follow-up. Eight patients who expired 
from progression-unrelated conditions (e.g., infarction and infection) were excluded from PFS analysis. To deter-
mine thresholds in each immune cell marker expression level for PFS, receiver operating curve analysis was used. 
Multivariate analysis was performed using the Cox proportional hazards model, which was adjusted for the prog-
nostic factors including the expression level of immune cell markers and IDH1 mutation status.
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